×

Before you go!

Sign up for the FREE weekly email newsletter from the publishers of American Nurse Today. You’ll get breaking news features, exclusive investigative stories, and more — delivered to your inbox.

Sign up today!

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
Drugs and Devices

FDA approves Korlym for hyperglycemia in patients with endogenous Cushing’s syndrome

On Feb. 17, the U.S. Food and Drug Administration (FDA) announced the approval of Korlym (mifepristone) to control hyperglycemia in adults with endogenous Cushing’s syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or who have not responded to prior surgery. Read more.


Leave a Reply

You have to agree to the comment policy.

 

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing

Shares